A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis.Frontiers in oncology · 2026
   Pooled it
2. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials.BMJ open · 2024
   Pooled it
3. Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial.Breast (Edinburgh, Scotland) · 2026
   Trial
4. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.Transplantation and cellular therapy · 2023
   Trial
5. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Nature medicine · 2023
   Trial
6. Retrospective Cohort Analysis of Treatment Patterns, Survival, and Cost-Effectiveness in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Lower Austria (2018-2022).Cancer medicine · 2026
   Article
7. Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.JAMA oncology · 2025
   Article
8. Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.The oncologist · 2025
   Article
9. Quality or quantity of life? Treatment priorities in older adults with cancer in the community.The oncologist · 2025
   Article
10. The Financial Toxicity Experience of Patients with Colorectal Cancer During Chemotherapy: A Qualitative Study.Current oncology (Toronto, Ont.) · 2024
    Article
11. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.BMJ oncology · 2024
    Article
12. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.Cancers · 2023
    Article
13. Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.The oncologist · 2023
    Article
14. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey.JCO oncology practice · 2023
    Article
15. Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
16. The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.Frontiers in pharmacology · 2023
    Article
17. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.Frontiers in public health · 2023
    Article
18. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.Patient related outcome measures · 2023
    Review
19. Physicians' Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer.Breast care (Basel, Switzerland) · 2022
    Article
20. Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years.Cancers · 2022
    Article

Corrections and comments

• Erratum for
  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).2015

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.